LAPC Search Results


  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • lapc4  (ATCC)
    93
    ATCC lapc4
    Chronic-ADT in hypoxia induces resistance to targeted disruption of androgen/AR-axis. a Schematic representation of repeated-ADT treatment of LNCaP and <t>LAPC4</t> cells in hypoxia (1% O 2 ) or normoxia (20% O 2 ). Cells were cultured in charcoal-stripped serum (CSS) media with or without 1 nM synthetic androgen R1881 (R1881 or ADT). Each round/cycle of treatment lasted 48 h, and the survived cells were recovered and re-plated for the same treatment in the following cycle. b Dose-dependent sensitivity of LNCaP clones to enzalutamide. Cells derived from a were cultured with CSS + R1881, and treated by increasing doses of enzalutamide in normoxia or hypoxia for 96 h. Afterwards, cell growth and viability were determined based on viable cells quantitated with SYTO 60 fluorescence staining and imaging. The AdtHs is represented by purple line. All values were mean ± s.d. relative to solvent-treated controls, n = 3. * P
    Lapc4, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/lapc4/product/ATCC
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    lapc4 - by Bioz Stars, 2021-05
    93/100 stars
      Buy from Supplier

    Image Search Results


    Chronic-ADT in hypoxia induces resistance to targeted disruption of androgen/AR-axis. a Schematic representation of repeated-ADT treatment of LNCaP and LAPC4 cells in hypoxia (1% O 2 ) or normoxia (20% O 2 ). Cells were cultured in charcoal-stripped serum (CSS) media with or without 1 nM synthetic androgen R1881 (R1881 or ADT). Each round/cycle of treatment lasted 48 h, and the survived cells were recovered and re-plated for the same treatment in the following cycle. b Dose-dependent sensitivity of LNCaP clones to enzalutamide. Cells derived from a were cultured with CSS + R1881, and treated by increasing doses of enzalutamide in normoxia or hypoxia for 96 h. Afterwards, cell growth and viability were determined based on viable cells quantitated with SYTO 60 fluorescence staining and imaging. The AdtHs is represented by purple line. All values were mean ± s.d. relative to solvent-treated controls, n = 3. * P

    Journal: Nature Communications

    Article Title: Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapy

    doi: 10.1038/s41467-018-07411-7

    Figure Lengend Snippet: Chronic-ADT in hypoxia induces resistance to targeted disruption of androgen/AR-axis. a Schematic representation of repeated-ADT treatment of LNCaP and LAPC4 cells in hypoxia (1% O 2 ) or normoxia (20% O 2 ). Cells were cultured in charcoal-stripped serum (CSS) media with or without 1 nM synthetic androgen R1881 (R1881 or ADT). Each round/cycle of treatment lasted 48 h, and the survived cells were recovered and re-plated for the same treatment in the following cycle. b Dose-dependent sensitivity of LNCaP clones to enzalutamide. Cells derived from a were cultured with CSS + R1881, and treated by increasing doses of enzalutamide in normoxia or hypoxia for 96 h. Afterwards, cell growth and viability were determined based on viable cells quantitated with SYTO 60 fluorescence staining and imaging. The AdtHs is represented by purple line. All values were mean ± s.d. relative to solvent-treated controls, n = 3. * P

    Article Snippet: Androgen-dependent prostate cancer cell lines LNCaP and LAPC4 were purchased from ATCC.

    Techniques: Cell Culture, Clone Assay, Derivative Assay, Fluorescence, Staining, Imaging

    FOXO1 interacts directly with ERG. A, Western blot analysis of endogenous FOXO1 and ERG proteins in VCaP cells immunoprecipitated by indicated antibody or non-specific IgG. B, Western blot analysis of ectopically expressed proteins immunoprecipitated by indicated antibody or non-specific IgG in PC-3 cells transfected with indicated Flag- and Myc-tagged plasmids. C , Schematic depicting a set of GST-ERG recombinant protein constructs. D, Coomassie Blue staining of GST and GST-ERG recombinant proteins purified from bacteria (bottom), and Western blot analysis of FOXO1 proteins in LAPC-4 cells pulled down by GST recombinant proteins (top). Red arrow, non-specific band. * in red, unexpected, but reproducible band shift. * in black, denotes expected fragment size. E, Schematic depicting a set of GST-FOXO1 recombinant protein constructs. F, GelCode Blue staining of GST and GST-FOXO1 recombinant proteins purified from bacteria (bottom), and Western blot analysis of in vitro transcribed and translated ERG proteins pulled down by GST recombinant proteins (top).

    Journal: Cancer research

    Article Title: Loss of FOXO1 cooperates with TMPRSS2-ERG overexpression to promote prostate tumorigenesis and cell invasion

    doi: 10.1158/0008-5472.CAN-17-0686

    Figure Lengend Snippet: FOXO1 interacts directly with ERG. A, Western blot analysis of endogenous FOXO1 and ERG proteins in VCaP cells immunoprecipitated by indicated antibody or non-specific IgG. B, Western blot analysis of ectopically expressed proteins immunoprecipitated by indicated antibody or non-specific IgG in PC-3 cells transfected with indicated Flag- and Myc-tagged plasmids. C , Schematic depicting a set of GST-ERG recombinant protein constructs. D, Coomassie Blue staining of GST and GST-ERG recombinant proteins purified from bacteria (bottom), and Western blot analysis of FOXO1 proteins in LAPC-4 cells pulled down by GST recombinant proteins (top). Red arrow, non-specific band. * in red, unexpected, but reproducible band shift. * in black, denotes expected fragment size. E, Schematic depicting a set of GST-FOXO1 recombinant protein constructs. F, GelCode Blue staining of GST and GST-FOXO1 recombinant proteins purified from bacteria (bottom), and Western blot analysis of in vitro transcribed and translated ERG proteins pulled down by GST recombinant proteins (top).

    Article Snippet: The cell lines VCaP, PC-3, and LAPC-4 were purchased from ATCC (Manassas, VA) and authenticated via STR profiling.

    Techniques: Western Blot, Immunoprecipitation, Transfection, Recombinant, Construct, Staining, Purification, Electrophoretic Mobility Shift Assay, In Vitro

    Inhibition of xenograft tumor growth, blood and tissue levels of arctigenin, and reduced expression of growth factors in SCID mice. Male SCID mice (n=10 per group) were inoculated subcutaneously with 5×10 5 androgen-sensitive LAPC-4 prostate tumor cells. The intervention treatments started either one week after (A, B) or two weeks prior to (C, D) the tumor cell inoculation. Arctigenin was administered daily through oral gavage at dose of 50mg/kg or 100mg/kg bw. Tumor size was measured twice a week using calipers and tumor volume calculated using the formula: length × width × height × 0.5236. Tumor weight was measured at mouse sacrifice. Blood and tumor levels of arctigenin (E) was detected with HPLC coupled with CoulArray electrochemical detector after extraction with ethyl acetate. The concentrations of 8 growth factors in tumor tissues were simultaneously measured using a Human Growth Factor ELISA Strip II kit (F). Data are presented as mean ± SD. Arc: arctigenin. Compared to control, *P

    Journal: Clinical nutrition experimental

    Article Title: Arctigenin inhibits prostate tumor cell growth in vitro and in vivo

    doi: 10.1016/j.yclnex.2017.04.001

    Figure Lengend Snippet: Inhibition of xenograft tumor growth, blood and tissue levels of arctigenin, and reduced expression of growth factors in SCID mice. Male SCID mice (n=10 per group) were inoculated subcutaneously with 5×10 5 androgen-sensitive LAPC-4 prostate tumor cells. The intervention treatments started either one week after (A, B) or two weeks prior to (C, D) the tumor cell inoculation. Arctigenin was administered daily through oral gavage at dose of 50mg/kg or 100mg/kg bw. Tumor size was measured twice a week using calipers and tumor volume calculated using the formula: length × width × height × 0.5236. Tumor weight was measured at mouse sacrifice. Blood and tumor levels of arctigenin (E) was detected with HPLC coupled with CoulArray electrochemical detector after extraction with ethyl acetate. The concentrations of 8 growth factors in tumor tissues were simultaneously measured using a Human Growth Factor ELISA Strip II kit (F). Data are presented as mean ± SD. Arc: arctigenin. Compared to control, *P

    Article Snippet: The androgen-sensitive LNCaP and LAPC-4 human prostate cancer cell lines were purchased from ATCC (Chicago, IL, USA).

    Techniques: Inhibition, Expressing, Mouse Assay, High Performance Liquid Chromatography, Enzyme-linked Immunosorbent Assay, Stripping Membranes